中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.01 seconds)

    NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT
    1.
    发明申请
    NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT 审中-公开
    抗癌治疗期间免疫系统的营养支持

    公开(公告)号：WO2010033424A2

    公开(公告)日：2010-03-25

    申请号：PCT/US2009/056583

    申请日：2009-09-11

    Applicant: NESTEC S.A. ,  SCHIFFRIN, Eduardo ,  MILLER, Kevin Burke ,  BRASSART, Dominique

    Inventor： SCHIFFRIN, Eduardo ,  MILLER, Kevin Burke ,  BRASSART, Dominique

    IPC: A61K35/74 ,  A61P35/00

    CPC classification number: A61K38/1783 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/195 ,  A61K31/20 ,  A61K31/7088 ,  A61K33/00 ,  A61K35/745 ,  A61K35/747 ,  A61K38/018 ,  A61K38/40 ,  A23V2200/324 ,  A23V2200/3204 ,  A23V2250/70 ,  A23V2250/54 ,  A23V2250/06 ,  A23V2200/308

    Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently augment or enhance the immunocompetence of an immune cell and the immunogenecity of a tumor cell of a subject undergoing anti-cancer therapy-induced apoptosis and tumor-cell-enhanced immunogenicity such that the innate and adaptive immune functions and normal physiology of the immune cell are preserved, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell and immunogenecity of the tumor cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.

    Abstract translation: 本发明涉及用于预防抗癌治疗期间免疫功能受损的方法和免疫营养组合物，从而获得更好的治疗效果。 更具体地，本发明涉及可以瞬时增强或增强免疫细胞的免疫能力的方法和免疫营养组合物，以及经历抗癌治疗诱导的细胞凋亡和肿瘤细胞增强的免疫原性的受试者的肿瘤细胞的免疫原性，如 保护免疫细胞的先天免疫功能和适应性免疫功能和正常生理学，进而导致（i）抗癌治疗更好的耐受性和增强的疗效; （ii）免疫细胞的免疫活性的瞬时增加或增强以及肿瘤细胞的免疫原性; 和（iii）通过抗癌治疗减弱的免疫细胞的免疫活性的影响和增加的优化。

    LACTIC ACID BACTERIA STRAINS USEFUL AGAINST UROGENITAL PATHOGENS AND COMPOSITIONS CONTAINING SAME
    2.
    发明申请
    LACTIC ACID BACTERIA STRAINS USEFUL AGAINST UROGENITAL PATHOGENS AND COMPOSITIONS CONTAINING SAME 审中-公开
    含有相同病原体的组合物及其组合物可用于乳酸菌菌株

    公开(公告)号：WO2006045473A1

    公开(公告)日：2006-05-04

    申请号：PCT/EP2005/011150

    申请日：2005-10-17

    Applicant: MEDINOVA AG ,  GRAF, Federico ,  GROB, Philipp ,  BRASSART, Dominique

    Inventor： GRAF, Federico ,  GROB, Philipp ,  BRASSART, Dominique

    IPC: A61K35/74 ,  A61P31/00

    CPC classification number: A61K35/747 ,  A23L2/382 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/02 ,  A61K9/48 ,  A61K2035/115 ,  C12R1/225 ,  C12R1/23 ,  Y02A50/473 ,  A61K2300/00 ,  A23V2200/32 ,  A23V2200/3204

    Abstract: Lactic acid bacteria strains of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii have been selected for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within vaginal epithelial cells, as well as for their ability to modulate a humoral and/or cellular immune response at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome. Pharmaceutical composition useful for preventing or treating urogenital infections in females which comprises a therapeutically effective amount of at least one of said strains in combination with a suitable galenical carrier.

    Abstract translation: 已经选择了嗜酸乳杆菌，脆性乳杆菌，加氏乳杆菌，瑞士乳杆菌和詹氏乳杆菌的乳酸菌菌株能够杀死泌尿生殖和/或胃肠道病原体及其抑制泌尿生殖和/ 或阴道上皮细胞内的胃肠道病原体，以及它们在阴道和/或胃肠道水平调节体液和/或细胞免疫应答的能力，特别是抑制炎性综合征以及感染性综合征的能力。 用于预防或治疗雌性泌尿生殖系统感染的药物组合物，其包含治疗有效量的至少一种所述菌株与合适的盖仑液体载体的组合。

    LACTOBACILLUS HELVETICUS STRAIN USEFUL IN THE TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY UROGENITAL PATHOGENS
    3.
    发明申请
    LACTOBACILLUS HELVETICUS STRAIN USEFUL IN THE TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY UROGENITAL PATHOGENS 审中-公开
    LACTOBACILLUS HELVETICUS菌株可用于治疗或预防UROGENITAL PATHOGENS引起的感染

    公开(公告)号：WO2006045347A1

    公开(公告)日：2006-05-04

    申请号：PCT/EP2005/001846

    申请日：2005-02-22

    Applicant: MEDINOVA AG ,  GRAF, Federico ,  GROB, Phillipp ,  BRASSART, Dominique

    Inventor： GRAF, Federico ,  GROB, Phillipp ,  BRASSART, Dominique

    IPC: A61K35/74

    CPC classification number: A61K35/747 ,  A23L2/382 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0034 ,  A61K9/0053 ,  A61K9/02 ,  A61K9/48 ,  A61K2035/115 ,  C12R1/225 ,  C12R1/23 ,  Y02A50/473 ,  A61K2300/00 ,  A23V2200/32 ,  A23V2200/3204

    Abstract: The L. helveticus strain LH KS 300 (CNCM I-3360) is used for its ability to adhere to cervix HeLa and/or Caco-2 epithelial cells, its ability to inhibit urogenital and/or gastrointestinal pathogens adhesion and growth on said epithelial cells, its ability to kill urogenital and/or gastrointestinal pathogens and its ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within said epithelial cells and also further selected for its ability to modulate the immune response of modulate the immuno competent cells, e.g. at the vaginal and/or gastrointestinal level, in particular to inhibit the inflammatory syndrome as well as the infectious syndrome. Pharmaceutical preparations containing said lactic acid bacteria strain useful for establishing, maintaining or restoring a balanced and healthy urogenital flora in females throughout life and corresponding methods of therapeutic or prophylactic treatment using them.

    Abstract translation: 使用瑞士螺杆菌LH KS 300（CNCM I-3360）具有粘附到子宫颈HeLa和/或Caco-2上皮细胞的能力，其在所述上皮细胞上抑制泌尿生殖和/或胃肠道病原体粘附和生长的能力 ，其杀死泌尿生殖和/或胃肠道病原体的能力及其抑制所述上皮细胞内泌尿生殖和/或胃肠道病原体内源化的能力，还进一步选择调节免疫感受态细胞的免疫应答的能力，例如 在阴道和/或胃肠道水平，特别是抑制炎性综合征以及感染性综合征。 含有所述乳酸菌菌株的药物制剂，其用于建立，维持或恢复整个生命中女性的平衡和健康的泌尿生殖菌群，以及使用它们的相应治疗或预防治疗方法。

    NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT
    7.
    发明申请
    NUTRITIONAL SUPPORT OF THE IMMUNE SYSTEM DURING ANTI-CANCER TREATMENT 审中-公开
    免疫系统在抗癌治疗过程中的营养支持

    公开(公告)号：WO2010033424A3

    公开(公告)日：2010-09-23

    申请号：PCT/US2009056583

    申请日：2009-09-11

    Applicant: NESTEC SA ,  SCHIFFRIN EDUARDO ,  MILLER KEVIN BURKE ,  BRASSART DOMINIQUE

    Inventor： SCHIFFRIN EDUARDO ,  MILLER KEVIN BURKE ,  BRASSART DOMINIQUE

    IPC: A23L33/00 ,  A61K31/195 ,  A61K31/20 ,  A61K31/7088 ,  A61K35/74 ,  A61K38/00 ,  A61K38/40 ,  A61P35/00 ,  A61P37/04

    CPC classification number: A61K38/1783 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/195 ,  A61K31/20 ,  A61K31/7088 ,  A61K33/00 ,  A61K35/745 ,  A61K35/747 ,  A61K38/018 ,  A61K38/40 ,  A23V2200/324 ,  A23V2200/3204 ,  A23V2250/70 ,  A23V2250/54 ,  A23V2250/06 ,  A23V2200/308

    Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently augment or enhance the immunocompetence of an immune cell and the immunogenecity of a tumor cell of a subject undergoing anti-cancer therapy-induced apoptosis and tumor-cell-enhanced immunogenicity such that the innate and adaptive immune functions and normal physiology of the immune cell are preserved, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell and immunogenecity of the tumor cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.

    Abstract translation: 本发明涉及预防抗癌治疗期间免疫功能受损的方法和免疫营养组合物，从而获得更好的治疗效果。 更具体地说，本发明涉及可瞬时增强或增强免疫细胞的免疫活性和经受抗癌疗法诱导的细胞凋亡和肿瘤细胞增强免疫原性的受试者的肿瘤细胞的免疫原性的方法和免疫营养组合物 确保免疫细胞的先天和适应性免疫功能和正常生理机能得以保持，这又导致（i）更好的耐受性和增加的抗癌疗法疗效; （ii）免疫细胞的免疫活性和肿瘤细胞的免疫原性的瞬时增强或增强; 和（iii）优化通过抗癌疗法减弱的免疫细胞的免疫活性的作用和增加免疫活性。

    LACTIC ACID BACTERIA STRAINS USEFUL AGAINST GASTROINTESTINAL PATHOGENS AND COMPOSITIONS CONTAINING SAME
    8.
    发明申请
    LACTIC ACID BACTERIA STRAINS USEFUL AGAINST GASTROINTESTINAL PATHOGENS AND COMPOSITIONS CONTAINING SAME 审中-公开
    乳酸菌菌株应用于胃肠道病原体和含有其的组合物

    公开(公告)号：WO2006045474A1

    公开(公告)日：2006-05-04

    申请号：PCT/EP2005/011151

    申请日：2005-10-17

    Applicant: MEDINOVA AG ,  GRAF, Federico ,  GROB, Philipp ,  BRASSART, Dominique

    Inventor： GRAF, Federico ,  GROB, Philipp ,  BRASSART, Dominique

    IPC: A61K35/74 ,  A61P31/00

    CPC classification number: C12R1/225 ,  A61K35/747

    Abstract: A method for preventing or treating gastrointestinal infections in humans comprises administering a pharmaceutical preparation which comprises, in combination with a suitable galenical carrier, a therapeutically effective amount of at least one strain of the genus L. acidophilus, L. crispatus, L. gasseri, L. helveticus and L. jensenii selected for their ability to kill urogenital and/or gastrointestinal pathogens and their ability to inhibit internalization of urogenital and/or gastrointestinal pathogens within gastrointestinal epithelial cells. Pharmaceutical composition useful for preventing or treating gastrointestinal infections in humans which comprises a therapeutically effective amount of at least one of said strains in combination with a suitable galenical carrier.

    Abstract translation: 一种用于预防或治疗人类胃肠道感染的方法包括施用药物制剂，其包含与合适的盖仑液体载体组合的治疗有效量的至少一种嗜酸乳杆菌L. crispatus，加氏乳杆菌， 由于其能够杀死泌尿生殖和/或胃肠道病原体以及抑制胃肠道上皮细胞内泌尿生殖和/或胃肠道病原体内化的能力，所以选择瑞士赫氏乳杆菌（L. helveticus）和詹氏乳杆菌（L. jensenii）。 可用于预防或治疗人类胃肠道感染的药物组合物，其包含治疗有效量的至少一种所述菌株与合适的盖仑液体载体的组合。

Patent Agency Ranking